These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 8714798)
1. Safety aspects of cyclosporin in rheumatoid arthritis. Dijkmans BA Drugs; 1995; 50 Suppl 1():41-7. PubMed ID: 8714798 [TBL] [Abstract][Full Text] [Related]
2. International consensus recommendations on cyclosporin use in rheumatoid arthritis. Tugwell P Drugs; 1995; 50 Suppl 1():48-56. PubMed ID: 8714799 [TBL] [Abstract][Full Text] [Related]
3. Microemulsion formulation of cyclosporin (Sandimmun Neoral) vs Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. On behalf of the OLR 302 Study Group. Yocum DE; Allard S; Cohen SB; Emery P; Flipo RM; Goobar J; Jayawardena S; Job-Deslandre C; Jubb RW; Krüger K; Lopes Vaz A; Manger B; Mur E; Nygaard H; Weiner SM; Rainer F; Sack MR; Schiff MH; Schnitzer TJ; Trigg LB; Whatmough I; Schmidt AG Rheumatology (Oxford); 2000 Feb; 39(2):156-64. PubMed ID: 10725065 [TBL] [Abstract][Full Text] [Related]
4. The use of Neoral in rheumatoid arthritis. Cranney A; Tugwell P Rheum Dis Clin North Am; 1998 Aug; 24(3):479-88. PubMed ID: 9710882 [TBL] [Abstract][Full Text] [Related]
6. Clinical use of cyclosporin in rheumatoid arthritis. Richardson C; Emery P Drugs; 1995; 50 Suppl 1():26-36. PubMed ID: 8714796 [TBL] [Abstract][Full Text] [Related]
7. Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporine: a double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics. Anderson IF; Helve T; Hannonen P; Leirisalo-Repo M; Gilboe IM; Nissilä M; Keystone EC; Kraag GR; Bjørneboe O; Chalmers A; Dovland H; Mueller E; Richard F; Whatmough I; Schmidt AG; Kovarik JM J Rheumatol; 1999 Mar; 26(3):556-62. PubMed ID: 10090162 [TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of conversion from stable Sandimmun maintenance treatment to Sandimmun Neoral in patients with rheumatoid arthritis. Flipo RM; Emery P; Scott DG; Situnayake RD; Prowse PJ; James DW; Cawley MI; Whatmough I; Schmidt AG J Rheumatol; 1998 Jul; 25(7):1263-9. PubMed ID: 9676754 [TBL] [Abstract][Full Text] [Related]
9. Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry. Rodríguez F; Krayenbühl JC; Harrison WB; Førre O; Dijkmans BA; Tugwell P; Miescher PA; Mihatsch MJ Arthritis Rheum; 1996 Sep; 39(9):1491-8. PubMed ID: 8814060 [TBL] [Abstract][Full Text] [Related]
10. Cyclosporin A therapy in rheumatoid arthritis: only strict application of the guidelines for safe use can prevent irreversible renal function loss. van den Borne BE; Landewé RB; Goei The HS; Breedveld FC; Dijkmans BA Rheumatology (Oxford); 1999 Mar; 38(3):254-9. PubMed ID: 10325664 [TBL] [Abstract][Full Text] [Related]
11. Combination therapy with cyclosporin in rheumatoid arthritis. Yocum DE Drugs; 1995; 50 Suppl 1():37-40. PubMed ID: 8714797 [TBL] [Abstract][Full Text] [Related]
12. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766 [TBL] [Abstract][Full Text] [Related]
13. Cyclosporin in rheumatoid arthritis: monitoring for adverse effects and clinically significant drug interactions. Dijkmans B; Gerards A BioDrugs; 1998 Dec; 10(6):437-45. PubMed ID: 18020613 [TBL] [Abstract][Full Text] [Related]
14. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability. Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413 [TBL] [Abstract][Full Text] [Related]
15. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation. Coukell AJ; Plosker GL Pharmacoeconomics; 1998 Dec; 14(6):691-708. PubMed ID: 10346420 [TBL] [Abstract][Full Text] [Related]
16. Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension. Kvien TK; Zeidler HK; Hannonen P; Wollheim FA; Førre O; Hafström I; Kaltwasser JP; Leirisalo-Repo M; Manger B; Laasonen L; Prestele H; Kurki P Ann Rheum Dis; 2002 Jun; 61(6):511-6. PubMed ID: 12006323 [TBL] [Abstract][Full Text] [Related]
17. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Noble S; Markham A Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033 [TBL] [Abstract][Full Text] [Related]
18. The use of Sandimmun (cyclosporin A) in severe refractory rheumatoid arthritis: the Belgian experience. Malaise MG; De Keyser P; De Backer M; van Lierde MA; Lesaffre E Clin Rheumatol; 1995 Sep; 14 Suppl 2():26-32. PubMed ID: 8846651 [TBL] [Abstract][Full Text] [Related]
19. Renal morphology after cyclosporin A therapy in rheumatoid arthritis patients. International Kidney Biopsy Registry of Cyclosporin (Sandimmun) in Autoimmune Diseases. Br J Rheumatol; 1993 Mar; 32 Suppl 1():65-71. PubMed ID: 8448642 [TBL] [Abstract][Full Text] [Related]
20. Long-term cyclosporin continuation rates in rheumatoid arthritis patients. Carpentier N; Bertin P; Druet-Cabanac M; Abdeddaïm M; Vergne P; Bonnet C; Trèves R Rev Rhum Engl Ed; 1999 May; 66(5):245-9. PubMed ID: 10380255 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]